Eidos Therapeutics (EIDX) Stock Price, News & Analysis

Company Overview

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Key Stats

• Today's Range: $122.21 to $122.21
• 50-Day Range: $120.98 to $128.51
• 52-Week Range: $28.39 to $132.54
• Volume: N/A
• Average Volume: 128,113 shs
• Market Capitalization: $4.75 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EIDX Stock Analysis - Frequently Asked Questions

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics, Inc. (NASDAQ:EIDX) posted its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.08. The company had revenue of $0.13 million for the quarter.

When did Eidos Therapeutics IPO?

Eidos Therapeutics (EIDX) raised $101 million in an initial public offering on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY).

Company Calendar

• Last Earnings: 10/29/2020
• Today: 8/02/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EIDX
• CIK: N/A
• Web: www.eidostx.com
• Phone: 415-887-1471
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -65.21%
• Return on Assets: -53.04%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 11.10
• Quick Ratio: 11.10

Sales & Book Value

• Annual Sales: $26.69 million
• Price / Sales: 177.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.57 per share
• Price / Book: 26.74

Miscellaneous

• Outstanding Shares: 38,873,000
• Free Float: N/A
• Market Cap: $4.75 billion
• Optionable: Not Optionable
• Beta: -0.16